Biogen Seeks FDA Approval for New Alzheimer’s Drug

Biogen is planning to file for U.S. regulatory approval for its Alzheimer’s treatment aducanumab after data from more patients in two discontinued studies showed that the drug improved cognition at high doses. Patients who received aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation, and language, Biogen said. In March, …

Biogen Seeks FDA Approval for New Alzheimer’s Drug Read More »